AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22682806
Drug: Gemcitabine (Gem)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (Gem) treatment arm with RT quality assurance per protocol and CA 19-9 <90 U/mL
Trial: 22682806
Drug: CA 19-9
RxNorm normalized name: CA-19-9 antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA 19-9 serum level ≥90 U/mL
Trial: 19125777
Drug: Glimepiride (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (titrated up to 6 mg/day, mean dose 4.5 mg/day)
Trial: 17381394
Drug: Ertapenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem (1 g qd)
Trial: 17381394
Drug: Piperacillin/tazobactam (3.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (3.375 g q6h)
Trial: 10402160
Drug: Thrice‐weekly buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice‐weekly buprenorphine dose schedules (64, 84, and 112 mg weekly)
Trial: 10402160
Drug: Daily buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily buprenorphine dose of 16 mg/70 kg
Trial: 10402160
Drug: Thrice‐weekly buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice‐weekly buprenorphine dose schedules
Trial: 12265803
Drug: ML Cu
RxNorm normalized name: SYRINGE 10-12ML CURVED TIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML Cu 250-standard
Trial: 12265803
Drug: ML Cu
RxNorm normalized name: SYRINGE 10-12ML CURVED TIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML Cu 250-short
Trial: 27783532
Drug: Sildenafil thermosensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil thermosensitive vaginal gel
Trial: 21251653
Drug: LMWH (enoxaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH (enoxaparin 40 mg, once daily) plus LDA
Trial: 21251653
Drug: UFH (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFH (5000 units, twice daily) plus LDA
Trial: 10749603
Drug: Intraperitoneal 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal 5-fluorouracil (5-FU) administered at 0.6 g/m2/day for 6 days (day 4 to day 10) plus intravenous 5-FU (1 g) during surgery
Trial: 10749603
Drug: Intraperitoneal 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraperitoneal 5-FU (full treatment)
Trial: 1525128
Drug: 60% phosphoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60% phosphoric acid gel with 0.5% NaF (Orthoprep) for 5 seconds
Trial: 1525128
Drug: 37% non‐fluoridated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37% non‐fluoridated phosphoric acid gel (Coe) for 60 seconds
Trial: 29431455
Drug: 90-minute Prolonged
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90-minute Prolonged Exposure therapy sessions
Trial: 29431455
Drug: 60-minute Prolonged
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-minute Prolonged Exposure therapy sessions
Trial: 25858265
Drug: Disease activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease activity guided dose reduction of adalimumab or etanercept
Trial: 23298304
Drug: Transanal, submucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transanal, submucosal injection of 4 x 1 mL of dextranomer in hyaluronic acid
Trial: 15134793
Drug: Activities of
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activities of Daily Living (ADL) skills training
Trial: 9215249
Drug: Cetirizine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (20 mg/day)
Trial: 31339474
Drug: CKD (eGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CKD (eGFR < 60 mL/min/1.73 m2)
Trial: 28775001
Drug: Intranasal theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal theophylline
Trial: 26036454
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (8-week randomized controlled trial)
Trial: 22104038
Drug: Cytisine (25-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytisine (25-day course of tablets)
Trial: 22104038
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) (usual care: eight weeks of NRT patch and/or gum or lozenge)
Trial: 14551293
Drug: Aggressive cytoreduction
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive cytoreduction with hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic chemotherapy (fluorouracil‐leucovorin)
Trial: 14551293
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment consisting of systemic chemotherapy (fluorouracil‐leucovorin) with or without palliative surgery
Trial: 7601919
Drug: Subgingival application
RxNorm normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival application of 2% minocycline ointment administered at baseline, week 2, and months 1, 3, 6, and 9.
Trial: 7601919
Drug: Systemic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic administration of minocycline following scaling/root planing for 10 days.
Trial: 7601919
Drug: Both subgingival
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both subgingival and systemic administration groups.
Trial: 30972456
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg/day)
Trial: 26523444
Drug: FOLFOX-A (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-A (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 2400 mg/m2, nab-paclitaxel 150 mg/m2 every 2 weeks)
Trial: 26523444
Drug: FOLFOX-A (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-A (oxaliplatin 65 mg/m2 if grade 2 neuropathy developed)
Trial: 21857520
Drug: Hyperbaric articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric articaine 84 mg (group A)
Trial: 21857520
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 7 mg along with fentanyl 10 μg (group B+F)
Trial: 7646751
Drug: One-month intensive
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-month intensive training program in psychosocial medicine
Trial: 23880099
Drug: Low-dose tranexamic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tranexamic acid (10 mg kg(‐1) followed by 1 mg kg(‐1) h(‐1) infusion and 1 mg kg(‐1) into the CPB)
Trial: 23880099
Drug: High-dose tranexamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tranexamic acid (30 mg kg(‐1) followed by 16 mg kg(‐1) h(‐1) infusion and 2 mg kg(‐1) into the CPB)
Trial: 14687273
Drug: Combination (COMBO)
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (COMBO)
Trial: 3926612
Drug: Nitroglycerin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patches delivering 5 mg/24 hours
Trial: 3926612
Drug: Nitroglycerin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patches delivering 10 mg/24 hours
Trial: 3926612
Drug: Nitroglycerin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patches delivering 20 mg/24 hours
Trial: 3926612
Drug: Nitroglycerin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patches delivering 30 mg/24 hours
Trial: 31988233
Drug: LEE011 (ribociclib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEE011 (ribociclib) 400 mg daily for 21 days
Trial: 30485685
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium administered 30 minutes before surgery.
Trial: 30485685
Drug: Saline administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administered 30 minutes before surgery (Control group).
Trial: 23589163
Drug: PTH(1-84) (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTH(1-84) (100 μg/day) + ibandronate (150 mg/month)
Trial: 15837454
Drug: Patient intervention
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient intervention (targeted communication about fall and fracture prevention and osteoporosis diagnosis and treatment delivered through mailings)
Trial: 10486394
Drug: Phenytoin 300
RxNorm normalized name: phenytoin 300 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin 300 mg/day
Trial: 10486394
Drug: Sodium Valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Valproate 1500 mg/day
Trial: 1797358
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg metaraminol
Trial: 1797358
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg metaraminol
Trial: 1797358
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg metaraminol
Trial: 1797358
Drug: Metaraminol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaraminol (all doses)
Trial: 29231297
Drug: Warm needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needling therapy applied to acupoints in the neck and lumbus (Fengchi (GB 20), Tianzhu (BL 10), Neck-Bailao (EX-HN 15), Wangu (GB 12), Tianyou (TE 16), Dachangshu (BL 25), Qihaishu (BL 24), Jiaji (EX-B 2) of L5). Treatment given once every two days, three times a week.
Trial: 29231297
Drug: Warm needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needling therapy applied only to acupoints in the neck (same as group A). Treatment given once every two days, three times a week.
Trial: 18781850
Drug: Fluvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin (80 mg/day, n = 420)
Trial: 16373648
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins (2 mg of folate, 25 mg of B6, and 400 microg of B12)
Trial: 9048404
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg once daily for 1 month (30 +/‐ 4 days)
Trial: 7849445
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg aspirin daily
Trial: 7849445
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg aspirin daily
Trial: 3315266
Drug: Evening administration
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administration at 2000 hr
Trial: 3315266
Drug: Evening administration
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administration at 2200 hr
Trial: 30136619
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation (5 capsules of fish-oil-derived omega-3, each 1 g containing 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid)
Trial: 24774260
Drug: Optimized glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized glucose control with insulin (target glucose, 80-120 mg/dL)
Trial: 24774260
Drug: Conventional control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional control (target glucose, <180 mg/dL)
Trial: 22660798
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) and TNF-α inhibitors
Trial: 16470437
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg before operation and twice thereafter at 8-hour intervals)
Trial: 12433712
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of insulin
Trial: 10651393
Drug: Leflunomide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (100 mg once daily for 3 days, then 20 mg once daily)
Trial: 1759005
Drug: Salbutamol 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 0.3 mg, tid + Beclomethasone dipropionate 0.2 mg, tid
Trial: 1759005
Drug: Salbutamol 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 0.3 mg, tid + Placebo
Trial: 6130076
Drug: Methaqualone 300
RxNorm normalized name: methaqualone 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methaqualone 300 mg
Trial: 31215299
Drug: Remote Ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote Ischemic Conditioning (RIC) treatment (4 cycles of 5-minute ischemia followed by 5-minute reperfusion)
Trial: 31215299
Drug: Sham-device treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-device treatment
Trial: 17511193
Drug: 0.05% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% betamethasone gel
Trial: 25797743
Drug: Dabrafenib 150
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib 150 mg po bid for 14 days
Trial: 25797743
Drug: Dabrafenib plus
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib plus trametinib 2 mg po daily for 14 days
Trial: 25797743
Drug: Dabrafenib therapy
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib therapy
Trial: 25797743
Drug: Dabrafenib and
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib and trametinib therapy
Trial: 22490614
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine formulae
Trial: 22490614
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine formulae (specifically Jing Fan Bai Du san)
Trial: 20968018
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (photon therapy)
Trial: 16043964
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (3 g/day)
Trial: 16043964
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir (8 g/day)
Trial: 12072104
Drug: HBV vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccination with levamisole (80 mg after each hemodialysis session for 4 months)
Trial: 10084038
Drug: Periarticular injection
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injection of 1.5 ml (40 mg/ml) methylprednisolone acetate and 1.5 ml (20 mg/ml) lignocaine (MP group)
Trial: 10084038
Drug: Isotonic sodium
RxNorm normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sodium chloride and 1.5 ml (20 mg/ml) lignocaine (non‐MP group)
Trial: 2187525
Drug: Intravenous treosulfan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous treosulfan
Trial: 2187525
Drug: Intravenous treosulfan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous treosulfan plus cisplatinum
Trial: 6142462
Drug: Alprazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.5 to 1 mg 3-times daily)
Trial: 29083258
Drug: Dienogest 2
RxNorm normalized name: dienogest 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dienogest 2 mg once daily for 24 weeks
Trial: 26791921
Drug: High-dose caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose caffeine (loading 20 mg/kg and maintenance of 15 mg/(kg·d) after 24 h)
Trial: 26791921
Drug: Low-dose caffeine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose caffeine (loading 20 mg/kg and maintenance of 5 mg/(kg·d) after 24 h)
Trial: 24902983
Drug: USL255 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USL255 (200 mg/day)
Trial: 9973769
Drug: 2.0 g
RxNorm normalized name: Fifty50 2.0 Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g vitamin C
Trial: 9973769
Drug: 105 g
RxNorm normalized name: soap/boric ac/sod lauryl sulf 105 gram TOPICAL CAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 105 g carbohydrate
Trial: 8268118
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (100 micrograms)
Trial: 20719809
Drug: Vaginal micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal micronized progesterone (200 mg, 3 times a day)
Trial: 18519268
Drug: Continuous-combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous-combined hormone replacement therapy (ccHRT) with estradiol valerate/medroxyprogesterone acetate (E(2)V/MPA) at dosages of 1 mg + 2.5 mg (n = 69), 1 mg + 5 mg (n = 70), or 2 mg + 5 mg (n = 140) for 8.5 years.
Trial: 18519268
Drug: Continuous-combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous-combined hormone replacement therapy (ccHRT) with estradiol valerate/medroxyprogesterone acetate (E(2)V/MPA)
Trial: 18519268
Drug: Post-discontinuation of
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discontinuation of ccHRT
Trial: 1724669
Drug: Iloprost infusion
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloprost infusion (0.5-0.2 ng/kg/min for 6 hours per day for 2 weeks)
Trial: 1724669
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion for 2 weeks
Trial: 6343462
Drug: Fluocortin butyl
RxNorm normalized name: fluocortin butyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocortin butyl (FCB) 2 mg
Trial: 6343462
Drug: Fluocortin butyl
RxNorm normalized name: fluocortin butyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocortin butyl (FCB) 4 mg
Trial: 6343462
Drug: Fluocortin butyl
RxNorm normalized name: fluocortin butyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocortin butyl (FCB) 8 mg
Trial: 26990694
Drug: Tacrolimus dosage
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus dosage determined by CYP3A5 genotype
Trial: 26990694
Drug: Fixed dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dosage of tacrolimus
Trial: 22013959
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel injection (2 ml, 3.5% micronised hyaluronic acid) using the fan technique
Trial: 22013959
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel injection (2 ml, 3.5% micronised hyaluronic acid) using the multiple puncture technique
Trial: 20846688
Drug: Bacillus Calmette‐Guérin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette‐Guérin with recommended daily allowance vitamins
Trial: 20846688
Drug: Bacillus Calmette‐Guérin/interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette‐Guérin/interferon α‐2b with recommended daily allowance vitamins
Trial: 17604562
Drug: Quyu Xiaoban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quyu Xiaoban capsules (QYXB) plus aspirin (300 mg loading dose, 100 mg maintenance dose)
Trial: 17604562
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg loading dose, 100 mg maintenance dose) plus baseline therapy
Trial: 16220098
Drug: Neuraminidase inhibitors
RxNorm normalized name: Neuraminidase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuraminidase inhibitors
Trial: 11215574
Drug: Clozapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (mean dose 28.78 mg/day)
Trial: 9623930
Drug: Treatment and
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment and sterilization guidelines introduced; seminars held at health centres; assessed 4 months post-intervention.
Trial: 30816851
Drug: Simultaneous (weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous (weight and diet tracking with weekly lessons, action plans, and feedback)
Trial: 30816851
Drug: Sequential (weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential (weight tracking for 4 weeks, then added diet tracking with the same behavioral components)
Trial: 28432876
Drug: Pistachio-supplemented diet
RxNorm normalized name: Pistachio
DrugBank: Pistachio (DB10559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistachio-supplemented diet (PD, 50% carbohydrates, 33% fat, including 57 g/d of pistachios daily)